Topic: Leukemia and Lymphoma

Leukemia and Lymphoma

Mar 2018 | Assessment

Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]